21 results
Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Thumbnail

D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Thumbnail

D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience

Thumbnail

D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital

Thumbnail

D3.429 - Performance Analysis of Five Large Language Models, Including GPTo1-Preview, On an Allergy and Clinical Immunology Exam

Thumbnail

D3.430 - Artificial intelligence Chatbots Can Influence the Decision-Making and Behavior of Patients with Allergies: Results of a Multicenter Evaluation Study

Thumbnail

D3.431 - Can Artificial Intelligence-Based Large Language Models Provide Accurate and Reliable Information to Asthma Patients? A Comparative Analysis with Expert Insights

Thumbnail

D3.432 - Anti-inflammatory properties of IPA on epithelial barrier sites

Thumbnail

D3.433 - Transcriptome kinetics of esophageal epithelial cells in response to interleukin 13

Thumbnail

D3.436 - Advancing Equity in Food Allergy Prevention – Insights and Takeaways from CFAAR’s Summit for Advancing Equity in Food Allergy

Thumbnail

D3.437 - An EAACI Task Force Initiative for Visualizing Historical Pollen and Spore Calendars in Europe

Thumbnail

D3.438 - Advances in Automated Pollen Monitoring in Mediterranean Regions: New Developments from the SYLVA Project in Córdoba (Spain)